Innoviva Total Non-Operating Income/Expense 2010-2024 | INVA
Innoviva total non-operating income/expense from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Innoviva Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$80 |
| 2022 |
$-187 |
| 2021 |
$70 |
| 2020 |
$33 |
| 2019 |
$-13 |
| 2018 |
$-28 |
| 2017 |
$-49 |
| 2016 |
$-49 |
| 2015 |
$-50 |
| 2014 |
$-40 |
| 2013 |
$-2 |
| 2012 |
$-6 |
| 2011 |
$-6 |
| 2010 |
$-6 |
| 2009 |
$-4 |
Innoviva Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-09-30 |
$-36 |
| 2024-06-30 |
$-94 |
| 2024-03-31 |
$19 |
| 2023-12-31 |
$24 |
| 2023-09-30 |
$68 |
| 2023-06-30 |
$-23 |
| 2023-03-31 |
$11 |
| 2022-12-31 |
$-89 |
| 2022-09-30 |
$-3 |
| 2022-06-30 |
$-62 |
| 2022-03-31 |
$-33 |
| 2021-12-31 |
$-48 |
| 2021-09-30 |
$29 |
| 2021-06-30 |
$40 |
| 2021-03-31 |
$50 |
| 2020-12-31 |
$6 |
| 2020-09-30 |
$-34 |
| 2020-06-30 |
$42 |
| 2020-03-31 |
$19 |
| 2019-12-31 |
$-3 |
| 2019-09-30 |
$-3 |
| 2019-06-30 |
$-3 |
| 2019-03-31 |
$-4 |
| 2018-12-31 |
$-4 |
| 2018-09-30 |
$-7 |
| 2018-06-30 |
$-6 |
| 2018-03-31 |
$-10 |
| 2017-12-31 |
$-8 |
| 2017-09-30 |
$-16 |
| 2017-06-30 |
$-13 |
| 2017-03-31 |
$-12 |
| 2016-12-31 |
$-12 |
| 2016-09-30 |
$-13 |
| 2016-06-30 |
$-11 |
| 2016-03-31 |
$-13 |
| 2015-12-31 |
$-13 |
| 2015-09-30 |
$-13 |
| 2015-06-30 |
$-13 |
| 2015-03-31 |
$-11 |
| 2014-12-31 |
$-16 |
| 2014-09-30 |
$-12 |
| 2014-06-30 |
$-10 |
| 2014-03-31 |
$-1 |
| 2013-12-31 |
$-1 |
| 2013-09-30 |
$-2 |
| 2013-06-30 |
$5 |
| 2013-03-31 |
$-4 |
| 2012-12-31 |
$-1 |
| 2012-09-30 |
$-1 |
| 2012-06-30 |
$-1 |
| 2012-03-31 |
$-1 |
| 2011-12-31 |
$-1 |
| 2011-09-30 |
$-1 |
| 2011-06-30 |
$-1 |
| 2011-03-31 |
$-1 |
| 2010-12-31 |
$-1 |
| 2010-09-30 |
$-1 |
| 2010-06-30 |
$-1 |
| 2010-03-31 |
$-1 |
| 2009-12-31 |
$-2 |
| 2009-09-30 |
$-1 |
| 2009-06-30 |
$-0 |
| 2009-03-31 |
$-1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.195B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
